Hanall Biopharma Co., Ltd. (009420) Price & Analysis

― Followers

009420 Stock Chart & Stats

₩39000.00

-₩2,700.00(-6.47%)

Jul 30, 2026

―

Day’s Range― - ―

52-Week Range₩25,550.00 - ₩73,000.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)520.26K

Market Cap

₩2.12T

Enterprise Value₩2.82M

Total Cash (Recent Filing)₩36.16B

Total Debt (Recent Filing)₩44.20B

Price to Earnings (P/E)―

Beta0.51

Next Earnings

Oct 22, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-102.22

Shares Outstanding52,240,640

10 Day Avg. Volume338,919

30 Day Avg. Volume520,265

Financial Highlights & Ratios

PEG Ratio-1.84

Price to Book (P/B)13.48

Price to Sales (P/S)14.05

P/FCF Ratio-662.91

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

009420 FAQ

What was Hanall Biopharma Co., Ltd.’s price range in the past 12 months?

Hanall Biopharma Co., Ltd. lowest stock price was ₩25550.00 and its highest was ₩73000.00 in the past 12 months.

What is Hanall Biopharma Co., Ltd.’s market cap?

Hanall Biopharma Co., Ltd.’s market cap is ₩2.12T.

When is Hanall Biopharma Co., Ltd.’s upcoming earnings report date?

Hanall Biopharma Co., Ltd.’s upcoming earnings report date is Oct 22, 2026 which is in 83 days.

How were Hanall Biopharma Co., Ltd.’s earnings last quarter?

Hanall Biopharma Co., Ltd. released its earnings results on Jul 29, 2026. The company reported -₩368.085 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Hanall Biopharma Co., Ltd. overvalued?

According to Wall Street analysts Hanall Biopharma Co., Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Hanall Biopharma Co., Ltd. pay dividends?

Hanall Biopharma Co., Ltd. does not currently pay dividends.

What is Hanall Biopharma Co., Ltd.’s EPS estimate?

Hanall Biopharma Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Hanall Biopharma Co., Ltd. have?

Hanall Biopharma Co., Ltd. has 52,240,640 shares outstanding.

What happened to Hanall Biopharma Co., Ltd.’s price movement after its last earnings report?

Hanall Biopharma Co., Ltd. reported an EPS of -₩368.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.743%.

Which hedge fund is a major shareholder of Hanall Biopharma Co., Ltd.?

Currently, no hedge funds are holding shares in KR:009420

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Hanall Biopharma Co., Ltd.

HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceuticals. It offers products such as medicine for digestion, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives, and other pharmaceutical products. The company was founded by Byeong-Tae Kim on November 20, 1973 and is headquartered in Daejeon, South Korea.